Emraclidine
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Emraclidine
- Molecular weight
- 390.41
- Structure (SMILES)
- Cc1cc(C)c2c(n1)CN(C(=O)CC1CN(c3ccnc(C(F)(F)F)c3)C1)C2
- 1 2 4 dimethyl 5 7 dihydro 6h pyrrolo 3 4 b pyridin 6 yl 2 1 2 trifluoromethyl pyridin 4 yl azetidin 3 yl ethanone
- 1-(2,4-DIMETHYL-5,7-DIHYDRO-6H-PYRROLO[3,4-B]PYRIDIN-6-YL)-2-{1-[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AZETIDIN-3-YL}ETHANONE
- cvl 231
- Cvl-231
- CVL-231
- emraclidine
- Emraclidine
- EMRACLIDINE
- emraclidine [INN]
- EMRACLIDINE [USAN]
- Emraclidine [WHO-DD]
- Emraclidine 10 mg
- Emraclidine 15 mg
- Emraclidine 30 mg
- emraclidine inn
- emraclidine usan
- emraclidine who dd
- pf 06852231
- Pf-06852231
- PF-06852231
- CAS registry numbers
- 2170722-84-4
- ChEMBL ID
- CHEMBL5314557
- InChIKey
- DTCZNKWBDTXEBS-UHFFFAOYSA-N
- PubChem compound IDs
- 140830653
- FDA ingredient codes (UNII)
- J241Y80EEO
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- emraclidine
- Type
- Synthetic organic
- Drug name stem
- -clidine
- Action
- Positive
- Action type
- POSITIVE
- Target
- M4 receptor
- Gene symbol
- CHRM4
- Protein identifier
- P08173
- Action
- Positive
- Action type
- POSITIVE
- Target
- M4 receptor
- Gene symbol
- CHRM4
- Protein identifier
- P08173
- Median affinity
- 7.91
- Affinity units
- pEC50
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Schizophrenia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005485
- Highest recorded phase
- 2
- NCT04136873
- NCT04787302
- NCT05106309
- NCT05227690
- NCT05227703
- NCT05245539
- NCT05443724
- NCT05935033
- NCT05940402
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 0
- Polar surface area
- 49.33
- Calculated partition coefficient (ALogP)
- 3.48
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 28
- Molecular formula
- C20H21F3N4O
- Monoisotopic mass
- 390.16674579
- Natural product
- No
- Recorded assays
- 48
- Active assays
- 16
Active assay types
- Confirmatory
Related records
Trials (17)
- A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
- A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
- A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants
- A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
- A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
- A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects
- A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
- A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
- A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
- A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants
- PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
- Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers
- The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants
- Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
In development for (3)
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Schizophrenia Phase 2